Affinage

ACVR2A

Activin receptor type-2A · UniProt P27037

Length
513 aa
Mass
57.8 kDa
Annotated
2026-06-09
55 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ACVR2A is a type II receptor of the TGF-β superfamily that nucleates ligand-induced heteromeric receptor complexes to transduce activin and BMP signals into the cell (PMID:35177083, PMID:35643319). Structurally, ACVR2A binds high-affinity ligands — activin A, activin B, and GDF11 — through a conserved hydrophobic hot spot, and its extracellular domain cooperatively assembles four-receptor complexes with type I receptors despite making no direct type I–type II contacts, increasing ligand affinity for the type I receptor ECD (PMID:12667445, PMID:35643319). At the plasma membrane ACVR2A forms stable heteromeric complexes with the activin type I receptor ALK4 and with BMP type I receptors ALK2, ALK3, and ALK6; ALK4 and the BMP type I receptors compete for ACVR2A, so differential complex formation balances signaling between the SMAD2/3 branch (ACVR2A/ALK4) and the SMAD1/5/8 branch (ACVR2A/ALK2 or ALK3) (PMID:35177083). Unlike the constitutively dimeric ACVR2B, ACVR2A homodimerizes only in the presence of activin A, a distinction that governs its ligand-dependent activation of the FOP-associated ALK2-R206H mutant (PMID:38334613). Physiologically, ACVR2A is the dominant type II receptor for activin-stimulated FSH production in pituitary gonadotropes, for endometrial BMP-SMAD1/5 signaling required for embryo implantation, and is a negative regulator of osteoblast bone formation acting through activin/SMAD2/3, with ACVR2B unable to substitute in these contexts (PMID:28659341, PMID:32270195, PMID:34099644). ACVR2A functions as a tumor suppressor in microsatellite-unstable gastrointestinal cancers, where it is biallelically inactivated by frameshift mutations in a polyadenine tract; restoration of wild-type receptor restores SMAD2 phosphorylation and suppresses growth, and activin-driven SMAD2 activation inhibits colon cancer migration, invasion, and epithelial-to-mesenchymal transition (PMID:12615714, PMID:15520171, PMID:37378449).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2003 High

    Establishing how ACVR2A assembles signaling complexes resolved whether type I and type II receptors contact each other directly, defining the architecture of superfamily signal transduction.

    Evidence X-ray crystallography of the BMP7–ACVR2A ECD complex with receptor truncation and membrane assembly binding assays

    PMID:12667445

    Open questions at the time
    • Did not resolve the full-length cytoplasmic kinase architecture
    • Cooperativity quantified for BMP7 but not other ligands
  2. 2003 High

    Discovery of recurrent biallelic frameshift inactivation in MSI gastrointestinal cancers reframed ACVR2A from a signaling receptor to a candidate tumor suppressor under selective pressure.

    Evidence Mutational sequencing and LOH analysis of 28 MSI colorectal and pancreatic tumors

    PMID:12615714

    Open questions at the time
    • Did not demonstrate the downstream signaling consequence of inactivation
    • Causal contribution to tumorigenesis not tested functionally
  3. 2004 Medium

    Re-expression rescue established the mechanistic link between ACVR2A loss and tumor phenotype by identifying SMAD2 phosphorylation and downstream AP-1/small GTPase programs as the effector output.

    Evidence Wild-type ACVR2A transfection into deficient MSI colon cancer cells with pSMAD2 Western blot, microarray, and growth assays

    PMID:15520171

    Open questions at the time
    • Single lab
    • AP-1 and GTPase gene induction correlative, not mechanistically dissected
  4. 2005 Medium

    Functional assays in prostate cancer lines and morphant zebrafish established that kinase-domain integrity is required for signaling and that ACVR2A has non-redundant developmental roles distinct from ACVR2B.

    Evidence Sequencing plus activin response assays in prostate lines; morpholino depletion and craniofacial phenotyping in zebrafish

    PMID:15977175 PMID:16337854

    Open questions at the time
    • Morpholino phenotypes lack genetic confirmation
    • Distinct ligand basis for ACVR2A/ACVR2B divergence not defined
  5. 2015 Medium

    Demonstrating that activin A competes for type II receptor occupancy revealed ACVR2A as a node where ligands antagonize each other to redirect BMP signaling through specific type I receptor complexes.

    Evidence Cell-based signaling competition assays with activin A and BMP ligands in myeloma lines

    PMID:26047946

    Open questions at the time
    • Specificity mapped functionally but not structurally
    • Single cell-line context
  6. 2017 High

    Conditional knockouts and granulosa-cell knockdown established ACVR2A as the dominant, ACVR2B-non-redundant type II receptor for both activin/SMAD2/3-mediated bone repression and BMP2/SMAD1/5/8 signaling.

    Evidence Osteoblast and granulosa-cell loss-of-function (osteocalcin-Cre KO; siRNA) with microCT, differentiation, and phospho-SMAD readouts

    PMID:28659341 PMID:28977600

    Open questions at the time
    • Ligand identity driving osteoblast repression not fully resolved
    • Granulosa findings from a single cell context
  7. 2020 High

    Gonadotrope-specific deletion with double-knockout controls established ACVR2A as the primary in vivo type II receptor for activin-stimulated FSH production and fertility.

    Evidence Cre-lox conditional KO of Acvr2a and/or Acvr2b in gonadotropes; serum FSH and fertility phenotyping

    PMID:32270195

    Open questions at the time
    • Partial redundancy with ACVR2B revealed only in double KO
    • Type I receptor partner in gonadotropes not defined here
  8. 2021 High

    Uterine conditional deletion identified an ACVR2A/SMAD1/5 BMP pathway as required for endometrial receptivity and implantation, with ACVR2B unable to substitute.

    Evidence PR-Cre conditional KO of Acvr2a, Acvr2b, and Smad1/5 with implantation and histological phenotyping

    PMID:34099644

    Open questions at the time
    • BMP ligand driving endometrial signaling not specified
    • Type I receptor partner in uterus not defined
  9. 2022 High

    Biophysical membrane diffusion and structural studies defined the molecular logic of branch selection: ALK4 versus BMP type I receptors compete for ACVR2A, and a conserved hydrophobic interface sets ligand specificity.

    Evidence FRAP lateral diffusion of immobilized receptors with signaling readouts; crystal structure of ACVR2A–activin A with binding-affinity profiling

    PMID:35177083 PMID:35643319

    Open questions at the time
    • Relied partly on receptor overexpression
    • Endogenous stoichiometry of competing complexes not measured
  10. 2023 Medium

    Selective SMAD2 (not SMAD3) activation downstream of ACVR2A was shown to mediate suppression of colon cancer migration, invasion, and EMT, sharpening the tumor-suppressor mechanism.

    Evidence Loss- and gain-of-function in colon cancer cells, in vivo experiments, phospho-SMAD blotting, and paired clinical samples

    PMID:37378449

    Open questions at the time
    • Single lab
    • Basis for SMAD2-over-SMAD3 selectivity unresolved
  11. 2024 High

    Mechanistic dissection of homodimerization explained the FOP-relevant divergence from ACVR2B: ACVR2A homodimerizes and activates ALK2-R206H only with activin A, whereas ACVR2B does so constitutively.

    Evidence FRAP immobilization diffusion measurements, BRE-Luc reporter, and pSMAD1/5/8 blotting comparing ACVR2A and ACVR2B

    PMID:38334613

    Open questions at the time
    • In cell-line overexpression context
    • Structural basis of ligand-dependent homodimerization not solved
  12. 2024 Medium

    Tumor-microenvironment studies extended ACVR2A loss-of-function to metabolic reprogramming, where SMAD-pathway inactivation drives hyperglycolysis, Treg accumulation, and immune-checkpoint resistance.

    Evidence Genetic knockdown and syngeneic mouse models, MCT4 pharmacological inhibition, and human HCC samples

    PMID:40139191

    Open questions at the time
    • Single lab
    • Direct mechanistic link from SMAD inactivation to LDHA/MCT4 not fully resolved
  13. 2025 Medium

    CRISPR knockout placed ACVR2A in control of trophoblast migration, proliferation, and invasion via a TCF7/c-JUN transcriptional program, complementing earlier trophoblast and decidual findings.

    Evidence CRISPR/Cas9 knockout in HTR8/SVneo and JAR trophoblast lines with RNA-seq and functional assays

    PMID:40444773

    Open questions at the time
    • Connection between canonical SMAD output and TCF7/c-JUN not delineated
    • In vitro cell lines only

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ACVR2A complex stoichiometry and type I receptor competition are regulated at endogenous expression to set SMAD2/3-versus-SMAD1/5/8 output across distinct physiological tissues remains unresolved.
  • No endogenous-level structural/stoichiometric measurement of competing complexes
  • Tissue-specific ligand and type I partner combinations incompletely mapped
  • Mechanism converting receptor loss into specific transcriptional/metabolic reprogramming not unified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0140096 catalytic activity, acting on a protein 3 GO:0048018 receptor ligand activity 1
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3
Partners
ALK2ALK3ALK4ALK6BMPR2SMAD1SMAD2
Complex memberships
ACVR2A/ALK2 BMP receptor complexACVR2A/ALK3 BMP receptor complexACVR2A/ALK4 activin receptor complex

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Crystal structure of BMP7 in complex with the extracellular domain (ECD) of ACVR2A reveals a cooperative four-receptor assembly model where type I and type II receptor ECDs make no direct contacts, yet truncated receptors lacking cytoplasmic domains retain cooperative assembly in the cell membrane; the affinity of BMP7 for its type I receptor ECD increases 5-fold in the presence of the ACVR2A ECD. X-ray crystallography; receptor truncation binding assays; cell membrane assembly experiments Molecular cell High 12667445
2003 ACVR2 (ACVR2A) undergoes inactivating frameshift mutations at an 8-bp polyadenine tract in gastrointestinal cancers with microsatellite instability (MSI), with biallelic mutations found in 25 of 28 MSI colorectal and pancreatic cancers, establishing ACVR2A as a candidate tumor suppressor gene whose inactivation is under strong selective pressure during gastrointestinal carcinogenesis. Mutational analysis by sequencing of primary tumor DNA; LOH analysis Cancer research High 12615714
2004 Restoration of wild-type ACVR2A in ACVR2-deficient MSI colon cancer cells decreased cell growth, increased phosphorylated SMAD2, and induced overexpression of TGF-β effector pathway genes including JUND, JUN, FOSB, RHOB, ARHE, and ARHGDIA, demonstrating that ACVR2A signals through SMAD2 phosphorylation and activates AP-1 and small GTPase signaling pathways. Wild-type ACVR2A transfection; Western blot for pSMAD2; microarray gene expression analysis; cell growth assay Cancer research Medium 15520171
2005 Truncating mutations in ACVR2A found in prostate cancer cell lines result in significantly reduced activin-mediated cell signaling, as measured by an activin response assay, demonstrating that the kinase domain integrity is required for ACVR2A signal transduction. Sequencing of ACVR2A in prostate cancer lines; activin response functional assay Cancer genetics and cytogenetics Medium 16337854
2005 In zebrafish, acvr2a and acvr2b exhibit distinct roles in craniofacial development: acvr2a morphants display defects in most cranial neural crest cell-derived cartilage, bone, and pharyngeal tooth structures, while acvr2b morphants show primarily posterior arch defects, establishing non-redundant functions for the two receptors. Morpholino-based protein depletion in zebrafish; phenotypic analysis of craniofacial structures Developmental dynamics Medium 15977175
2015 Activin A antagonizes BMP-6 and BMP-9 (but not BMP-2 or BMP-4) by competing for binding to ACVR2A and ACVR2B, thereby inhibiting BMP signaling through ALK2-coupled receptor complexes but not through BMPR2/ALK3/ALK6 complexes. Cell-based signaling assays with activin A and BMP ligands; receptor expression characterization in myeloma cell lines Cell communication and signaling : CCS Medium 26047946
2017 Conditional deletion of ACVR2A in osteoblasts (using osteocalcin-Cre) results in significantly increased femoral trabecular bone volume and enhanced osteoblast differentiation in vitro (alkaline phosphatase activity, mineral deposition, osterix/osteocalcin/DMP1 expression), while ACVR2B deletion has no significant effect, establishing ACVR2A as the dominant negative regulator of bone mass in osteoblasts via activin/SMAD2/3 signaling. Conditional knockout mice (osteocalcin-Cre); microCT bone analysis; primary osteoblast culture; in vitro differentiation assays; immunohistochemistry The Journal of biological chemistry High 28659341
2017 BMP2 signals through ALK2/ALK3 type I receptors and BMPR2/ACVR2A type II receptors to phosphorylate SMAD1/5/8 and suppress PTX3 expression in human granulosa-lutein cells; knockdown of ACVR2A completely reverses BMP2-induced SMAD1/5/8 phosphorylation and restores PTX3 expression. siRNA knockdown of ACVR2A and other receptors; Western blot for pSMAD1/5/8; qRT-PCR for PTX3; pharmacological receptor inhibition Endocrinology Medium 28977600
2020 Gonadotrope-specific conditional deletion of Acvr2a in mice causes marked decreases in serum FSH, subfertility in females, and hypogonadism in males; simultaneous deletion of Acvr2a and Acvr2b causes profound FSH deficiency and sterility, establishing ACVR2A as the primary type II receptor mediating activin-stimulated FSH production in pituitary gonadotropes in vivo. Cre-lox conditional knockout (Acvr2a and/or Acvr2b in gonadotropes); serum FSH measurement; fertility assessment; testicular weight analysis Endocrinology High 32270195
2021 BMP signaling controls endometrial receptivity via a conserved ACVR2A/SMAD1/5 signaling pathway; conditional deletion of Acvr2a in uterine cells (PR-Cre) impairs BMP signaling and leads to defective implantation, while ACVR2B deletion does not affect implantation, establishing ACVR2A as the requisite type II receptor for endometrial BMP-SMAD1/5 signaling during embryo implantation. Conditional knockout mice (PR-Cre for Acvr2a, Acvr2b, Smad1/5); fertility/implantation phenotyping; histological analysis Nature communications High 34099644
2022 ACVR2A forms stable heteromeric complexes at the plasma membrane with ALK4 (activin type I receptor) and with BMP type I receptors ALK2, ALK3, and ALK6; ALK4 and BMP type I receptors compete for binding to ACVR2A, and differential complex formation of distinct type I receptors with ACVR2A balances signaling between SMAD2/3 (via ACVR2A/ALK4 in activin A signaling) and SMAD1/5/8 (via ACVR2A/ALK2 or ALK3 in BMP9 signaling). IgG-mediated patching-immobilization combined with FRAP measurements of lateral diffusion; receptor overexpression competition; downstream signaling readouts (pSMAD2/3 and pSMAD1/5/8) BMC biology High 35177083
2022 Crystal structure of ACVR2A in complex with activin A shows that ACVR2A binds activin A (and activin B) with high affinity using a conserved hydrophobic hot spot geometry nearly identical to BMPR2; high-affinity ligands for ACVR2A are activin A, activin B, and GDF11, whereas those for BMPR2 are BMP15, BMP10, and Nodal. X-ray crystallography of ACVR2A-activin A complex; in vitro binding affinity measurements The Journal of biological chemistry High 35643319
2023 Activin A binding to ACVR2A selectively activates SMAD2 (but not SMAD3) transcription to inhibit colon cancer cell migration, invasion, and epithelial-to-mesenchymal transition; ACVR2A downregulation is associated with loss of this suppressive signaling in colorectal cancer metastasis. Loss-of-function and gain-of-function experiments in colon cancer cells; in vivo animal experiments; Western blot for pSMAD2/3; migration/invasion assays; paired clinical sample analysis Molecular carcinogenesis Medium 37378449
2024 ACVR2A impairment induces hyperglycolysis through inactivation of the SMAD signaling pathway, causing upregulation of LDHA and MCT4 expression, increased lactate secretion, and Treg cell accumulation in the tumor microenvironment, leading to resistance to immune checkpoint inhibitors; MCT4 inhibition restores anti-tumor immunity in ACVR2A-deficient HCC. Genetic knockdown and syngeneic transplantation mouse models; pharmacological MCT4 inhibition; human clinical sample analysis; Western blot for SMAD signaling Cell reports. Medicine Medium 40139191
2024 ACVR2A forms homodimers only in the presence of activin A (ActA), while ACVR2B forms stable homodimers without ligand; this distinction dictates their ability to activate the FOP-inducing ALK2-R206H mutant — ACVR2B activates ALK2-R206H without ligand, whereas ACVR2A activation of ALK2-R206H requires ActA. Both receptors form heteromeric complexes with ALK2-R206H, with ACVR2B being more efficient. IgG-mediated receptor immobilization + FRAP lateral diffusion measurements; BRE-Luc reporter transcriptional assays; pSMAD1/5/8 Western blotting Cells High 38334613
2025 CRISPR/Cas9-mediated deletion of ACVR2A in trophoblast cell lines (HTR8/SVneo and JAR) inhibits trophoblast migration, proliferation, and invasion; RNA-seq analysis reveals that ACVR2A signals through the TCF7/c-JUN pathway to regulate these trophoblast functions. CRISPR/Cas9 knockout; RNA-seq; RT-PCR; immunohistochemistry; functional migration/invasion/proliferation assays eLife Medium 40444773
2015 A susceptibility variant in the ACVR2A promoter (rs1424954 A>G) causes downregulation of ACVR2A expression in trophoblasts; ACVR2A knockdown in SGHPL-5 trophoblasts leads to reduced NODAL mRNA expression upon physiologic activin A stimulation (suggesting increased trophoblast invasion potential), but this protective effect is lost at pathologic activin A concentrations seen in pre-eclampsia. Promoter-reporter transfections in SGHPL-5 trophoblasts; siRNA knockdown of ACVR2A; qRT-PCR for NODAL Placenta Medium 25659497
2014 miR-590 directly targets Acvr2a to suppress activin signaling in mouse ESCs; downregulation of Acvr2a by miR-590 promotes Rad51b-mediated homologous recombination repair of single-strand and double-strand breaks, balancing DNA damage repair with rapid proliferation during self-renewal. miRNA target validation; Acvr2a knockdown; DNA damage repair assays; cell cycle analysis Stem cell reports Medium 25458897
2018 Downregulation of Acvr2a in pre-iPSCs (via miR-590 overexpression or shRNA) promotes telomere elongation and pluripotency acquisition; mechanistically, p-SMAD2 binds the Terf1 promoter in pre-iPSCs, and inhibition of Acvr2a/Activin signaling increases Terf1 expression, which mediates telomere re-elongation. miR-590 overexpression; shRNA knockdown of Acvr2a; ChIP for pSMAD2 at Terf1 promoter; telomere length assays; pluripotency assays Stem cell reports Medium 29910124
2017 Decidual ACVR2A activity, as modeled in St-T1b cells, regulates trophoblast adhesion, proliferation, migration, and invasion in vitro via paracrine signaling; siRNA knockdown of ACVR2A in decidual cells attenuated the inhibitory effects of conditioned medium on all four trophoblast functions. siRNA knockdown of ACVR2A in decidual stromal cell line; conditioned medium transfer; functional trophoblast assays Pregnancy hypertension Low 29203340
2024 ACVR2A mediates TGF-β1/Smad signaling in hepatic stellate cells; Echinacoside exerts antifibrotic effects by modulating ACVR2A expression, and both inhibition and induction of ACVR2A in LX-2 cells confirmed it as a regulator of the TGF-β1/Smad fibrotic axis. Transcriptome analysis; ACVR2A knockdown and induction in LX-2 cells; in vivo high-fat diet mouse model; functional cell proliferation and migration assays Molecular nutrition & food research Low 38366962
2024 ACVR2A suppression in colorectal cancer cells under hypoxia activates the PI3K/AKT/mTOR pathway, upregulates MMP3, CyclinA, CyclinD1, and HIF1α, and promotes angiogenesis; in vitro experiments confirmed ACVR2A suppresses CRC proliferation, migration, and invasion. In vitro transwell migration/invasion assays; colony formation; Western blot for PI3K/AKT/mTOR pathway proteins; angiogenesis assay; in vivo tumor experiments Scientific reports Low 38898042
2011 Acvr2a is specifically induced during Th17 cell differentiation and requires both TGF-β and IL-6 for its induction; its expression is not seen in Th1 or Th2 cells and is inhibited when Th17 differentiation is blocked by ATRA. Gene expression analysis during T helper cell differentiation; cytokine dependency experiments; ATRA inhibition of Th17 differentiation Bioscience, biotechnology, and biochemistry Low 22056434
2025 A novel ACVR2A::RAF1 fusion protein (comprising the first four exons of ACVR2A and the last nine exons of RAF1, retaining ACVR2A extracellular and transmembrane domains fused to the RAF1 kinase domain) drives spindle cell sarcoma tumorigenesis and responds to MEK inhibitor trametinib treatment. Next-generation sequencing identifying fusion; clinical response to trametinib as functional validation Genes, chromosomes & cancer Low 39950347

Source papers

Stage 0 corpus · 55 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Molecular cell 224 12667445
2019 Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis. Molecular cancer 135 31101108
2015 Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell communication and signaling : CCS 131 26047946
2003 Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer research 98 12615714
2021 Endometrial receptivity and implantation require uterine BMP signaling through an ACVR2A-SMAD1/SMAD5 axis. Nature communications 71 34099644
2016 ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skeletal muscle 70 27462398
2017 Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass. The Journal of biological chemistry 55 28659341
2008 Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). European journal of human genetics : EJHG 51 18781190
2012 BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II. Angiogenesis 43 22622516
2004 Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Cancer research 37 15520171
2009 Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Molecular human reproduction 32 19126782
2017 ALK2/ALK3-BMPR2/ACVR2A Mediate BMP2-Induced Downregulation of Pentraxin 3 Expression in Human Granulosa-Lutein Cells. Endocrinology 29 28977600
2014 A miR-590/Acvr2a/Rad51b axis regulates DNA damage repair during mESC proliferation. Stem cell reports 27 25458897
2022 Competition between type I activin and BMP receptors for binding to ACVR2A regulates signaling to distinct Smad pathways. BMC biology 25 35177083
2005 Zebrafish acvr2a and acvr2b exhibit distinct roles in craniofacial development. Developmental dynamics : an official publication of the American Association of Anatomists 25 15977175
2003 The interaction of BMP-7 and ActRII implicates a new mode of receptor assembly. Trends in biochemical sciences 25 14559178
2020 Murine FSH Production Depends on the Activin Type II Receptors ACVR2A and ACVR2B. Endocrinology 24 32270195
2005 Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells. Cancer genetics and cytogenetics 24 16337854
2024 Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway. Molecular cancer 23 39107843
2019 Comparative analysis of silencing expression of myostatin (MSTN) and its two receptors (ACVR2A and ACVR2B) genes affecting growth traits in knock down chicken. Scientific reports 22 31127166
2008 Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PloS one 22 18941508
2014 Association between ACVR2A and early-onset preeclampsia: replication study in a Northeastern Brazilian population. Placenta 20 25499008
2006 Involvement of the bone morphogenetic protein/receptor system during follicle development in the bovine ovary: Hormonal regulation of the expression of bone morphogenetic protein 7 (BMP-7) and its receptors (ActRII and ALK-2). Molecular and cellular endocrinology 20 16513253
2025 ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. Cell reports. Medicine 17 40139191
2018 Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMS. Proteomics. Clinical applications 17 29226558
2018 Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS. Drug testing and analysis 16 30285318
2022 Downregulation of miR-192 Alleviates Oxidative Stress-Induced Porcine Granulosa Cell Injury by Directly Targeting Acvr2a. Cells 15 35954205
2003 Loss of heterozygosity and mutational analyses of the ACTRII gene locus in human colorectal tumors. Laboratory investigation; a journal of technical methods and pathology 14 14691305
2022 Type II BMP and activin receptors BMPR2 and ACVR2A share a conserved mode of growth factor recognition. The Journal of biological chemistry 12 35643319
2020 Microsatellite Instability-Related ACVR2A Mutations Partially Account for Decreased Lymph Node Metastasis in MSI-H Gastric Cancers. OncoTargets and therapy 11 32440149
2015 ACVR2A promoter polymorphism rs1424954 in the Activin-A signaling pathway in trophoblasts. Placenta 11 25659497
2011 Association of the rs1424954 polymorphism of the ACVR2A gene with the risk of pre-eclampsia is not replicated in a Finnish study population. BMC research notes 11 22177086
2018 Targeted sequencing analysis of ACVR2A gene identifies novel risk variants associated with preeclampsia. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 10 29506428
2018 Association between 3'UTR polymorphisms in genes ACVR2A, AGTR1 and RGS2 and preeclampsia. General physiology and biophysics 10 29593124
2024 Echinacoside Exerts Antihepatic Fibrosis Effects in High-Fat Mice Model by Modulating the ACVR2A-Smad Pathway. Molecular nutrition & food research 9 38366962
2023 Activin A/ACVR2A axis inhibits epithelial-to-mesenchymal transition in colon cancer by activating SMAD2. Molecular carcinogenesis 9 37378449
2019 Does the expression of the ACVR2A gene affect the development of colorectal cancer? Genetics and molecular biology 8 30856244
2019 Association between ACVR2A gene polymorphisms and risk of hypertensive disorders of pregnancy in the northern Chinese population. Placenta 8 31790936
2017 Decidual ACVR2A regulates extravillous trophoblast functions of adhesion, proliferation, migration and invasion in vitro. Pregnancy hypertension 8 29203340
2011 Identification of Acvr2a as a Th17 cell-specific gene induced during Th17 differentiation. Bioscience, biotechnology, and biochemistry 8 22056434
2025 ActRII or BMPR ligands inhibit skeletal myoblast differentiation, and BMPs promote heterotopic ossification in skeletal muscles in mice. Skeletal muscle 7 39994804
2024 Sponging of five tumour suppressor miRNAs by lncRNA-KCNQ1OT1 activates BMPR1A/BMPR1B-ACVR2A/ACVR2B signalling and promotes chemoresistance in hepatocellular carcinoma. Cell death discovery 7 38851743
2018 The miR-590/Acvr2a/Terf1 Axis Regulates Telomere Elongation and Pluripotency of Mouse iPSCs. Stem cell reports 7 29910124
2019 Non-additive effects of ACVR2A in preeclampsia in a Philippine population. BMC pregnancy and childbirth 6 30621627
2011 Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within activin receptor 2 (ACVR2). Mutation research 6 22001236
2021 Isolated and Sporadic Human Mesiodens Is Associated with a Synonymous Variant in the ACVR2A Gene. Pediatric dentistry 5 33662249
2022 CircRNA ACVR2A Sponges miR-1290 to Modulate Cell Progression in Gastric Cancer. Journal of oncology 3 35186081
2025 ACVR2A facilitates trophoblast cell invasion through TCF7/c-JUN pathway in pre-eclampsia progression. eLife 2 40444773
2024 The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A. Cells 2 38334613
2024 Identification of 8 candidate microsatellite instability loci in colorectal cancer and validation of the ACVR2A mechanism in the tumor progression. Scientific reports 2 38898042
2023 Characterization of Fibrodysplasia Ossificans Progessiva relevant Acvr1/Acvr2 Activin receptors in medaka (Oryzias latipes). PloS one 2 37708126
1996 Cloning of the bovine activin receptor type II gene (ACVR2) and mapping to chromosome 2 (BTA2). Cytogenetics and cell genetics 1 8995483
2025 The First Evidence for the Role of ACVR2A Gene Fetal Genotype in Preeclampsia Susceptibility. Molecular genetics & genomic medicine 0 39898504
2025 A Novel ACVR2A::RAF1 Fusion in Spindle Cell Sarcoma. Genes, chromosomes & cancer 0 39950347
2022 BAT25, ACVR2, and TGFBR2 Mononucleotide STR Markers: A Triplex Panel for Microsatellite Instability Testing in Colorectal Tumors. Advanced biomedical research 0 36393819

Missed literature

Know a paper Affinage missed for ACVR2A? Flag it for the maintainers and the community.

No submissions yet.